{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:14Z","timestamp":1793090294153,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105598","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:33:00Z","timestamp":1789540380000},"page":"105598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy"],"prefix":"10.1016","volume":"227","author":[{"given":"Serina","family":"Easmin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita","family":"Palai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moulik","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiran","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhin Subhra","family":"Jana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishanu","family":"Gucchait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-2459","authenticated-orcid":false,"given":"Priya","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105598_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102428","article-title":"Clinical trial data of anti\u2013PD-1\/PD-L1 therapy for recurrent or metastatic nasopharyngeal carcinoma: a review","volume":"109","author":"Adkins","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105598_bib2","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.1007\/s00210-025-03901-w","article-title":"Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding","volume":"398","author":"Ahmed","year":"2025","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1834585","article-title":"Engineering strategies and binding mechanisms of therapeutic anti\u2013PD-1 antibodies approved by regulatory agencies globally","volume":"17","author":"Almagro","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1401515","article-title":"Navigating the landscape of PD-1\/PD-L1 imaging tracers: from challenges to opportunities","volume":"11","author":"Badenhorst","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.critrevonc.2026.105598_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105598_bib6","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1097\/JS9.0000000000003154","article-title":"Comment on \u201cEfficiency and safety of neoadjuvant PD-1 inhibitor (penpulimab) combined with chemotherapy in resectable N1\/N2 non-small cell lung cancer: a prospective cohort study","volume":"111","author":"Bai","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105598_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113530","article-title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","volume":"199","author":"Brahmer","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":". 1","key":"10.1016\/j.critrevonc.2026.105598_bib8","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1182\/blood-2024-203156","article-title":"TQB2223 in combination with penpulimab in patients with relapsed or refractory lymphoma: primary analysis of an open-label phase I study","volume":"144","author":"Cai","year":"2024","journal-title":"Blood"},{"issue":". 2","key":"10.1016\/j.critrevonc.2026.105598_bib9","first-page":"A471","article-title":"Population pharmacokinetics of an anti-PD-1 antibody, penpulimab in patients with advanced malignancies","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105598_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41392-024-01865-6","article-title":"Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105598_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2174\/0113895575415429251007093531","article-title":"Unlocking the immune system: advances in next-generation immunotherapy for lung cancer","volume":"26","author":"Choudhary","year":"2026","journal-title":"Mini Rev. Med. Chem."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105598_bib12","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s40265-021-01640-9","article-title":"Penpulimab: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"2.","key":"10.1016\/j.critrevonc.2026.105598_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1200\/JCO.2026.44.2_suppl.655","article-title":"Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: a multi-centered, randomized controlled trial (RCT-PAAG)","volume":"44","author":"Du","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib14","unstructured":"(FDA)., U. S. F. A. D. A 2025. FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma.: U.S. FOOD AND DRUG ADMINISTRATION (FDA). April 13, 2025, from (https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma) ."},{"key":"10.1016\/j.critrevonc.2026.105598_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1114994","article-title":"A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab","volume":"14","author":"Gao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.684867","article-title":"Clinical activity and safety of penpulimab (anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-label, multicenter, phase Ib\/II trial (AK105-203)","volume":"11","author":"Han","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105598_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40261-025-01439-6","article-title":"Economic evaluation of penpulimab plus paclitaxel and carboplatin combination therapy as first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer in China","volume":"45","author":"Han","year":"2025","journal-title":"Clin. Drug. Investig."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105598_bib18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/10600280251391430","article-title":"Toripalimab and penpulimab: targeting PD-1 in recurrent or metastatic nasopharyngeal carcinoma","volume":"60","author":"Hockett","year":"2026","journal-title":"Ann. Pharmacother."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105598_bib19","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med."},{"issue":"8. 2","key":"10.1016\/j.critrevonc.2026.105598_bib20","doi-asserted-by":"crossref","first-page":"CT011","DOI":"10.1158\/1538-7445.AM2025-CT011","article-title":"Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)","volume":"85","author":"Hu","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105598_bib21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41392-026-02645-0","article-title":"Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study","volume":"11","author":"Huang","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105598_bib22","article-title":"Penpulimab, an Fc-engineered IgG1 anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"issue":"15.","key":"10.1016\/j.critrevonc.2026.105598_bib23","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1200\/JCO.2020.38.15_suppl.4592","article-title":"Clinical activity and safety of penpulimab (anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC)","volume":"38","author":"Jiao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105598_bib25","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.2147\/CMAR.S379911","article-title":"A real-world study of optimal treatment with anlotinib first-line therapy in advanced hepatocellular carcinoma","volume":"14","author":"Li","year":"2022","journal-title":"Cancer Manag. Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105598_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000042730","article-title":"Penpulimab in an adolescent patient with pancreatic neuroendocrine carcinoma with liver metastasis: a case report and literature review","volume":"104","author":"Li","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2026.105598_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557461","article-title":"Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1\/PD-L1 therapy","volume":"16","author":"Liao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib29","article-title":"PD-1 N58-glycosylation-dependent binding of monoclonal antibody cemiplimab for immune checkpoint therapy","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1785587","article-title":"From immune exclusion to exhaustion: tumor microenvironment drives therapy response","volume":"17","author":"Maletin","year":"2026","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105598_bib31","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105598_bib32","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.3390\/ijms24076710","article-title":"The efficacy of tumor mutation burden as a biomarker of response to immune checkpoint inhibitors","volume":"24","author":"Moeckel","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105598_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105598_bib34","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s12325-021-01638-5","article-title":"Fixed dose of cemiplimab in patients with advanced malignancies based on population pharmacokinetic analysis","volume":"38","author":"Paccaly","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105598_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107989","article-title":"Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy","volume":"197","author":"Qiu","year":"2024","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105598_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00262-024-03635-3","article-title":"Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells","volume":"73","author":"Rajasekaran","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105598_bib37","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3390\/diagnostics11081452","article-title":"PD-L1 expression in non-small cell lung cancer: data from a referral center in Spain","volume":"11","author":"Saez de Gordoa","year":"2021","journal-title":"Diagnostics"},{"issue":"40","key":"10.1016\/j.critrevonc.2026.105598_bib38","article-title":"Therapeutic efficacy of nanocarrier-mediated inhalable gene transfection for lung cancer","volume":"9","author":"Sarkar","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.critrevonc.2026.105598_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.871372","article-title":"Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: a systematic review","volume":"13","author":"Shang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41417-026-01000-3","article-title":"Exploration of the mechanism of anlotinib in reversing PD-1 immunotherapy resistance: insights from single-cell sequencing","volume":"33","author":"Shi","year":"2026","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105598_bib41","article-title":"Penpulimab combined with anlotinib in patients with R\/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase II study","volume":"8","author":"Shi","year":"2023","journal-title":"ESMO Open."},{"issue":". 5","key":"10.1016\/j.critrevonc.2026.105598_bib42","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2021.08.1318","article-title":"Efficacy and safety of penpulimab plus anlotinib in recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): a phase II study","volume":"32","author":"Shi","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib43","article-title":"Penpulimab for relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, pivotal phase I\/II trial (AK105-201)","volume":"12","author":"Song","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105598_bib44","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105598_bib45","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1159\/000543520","article-title":"Analysis of immune-related adverse events of pembrolizumab using FAERS database","volume":"103","author":"Tan","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2026.105598_bib46","article-title":"Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China","volume":"15","author":"Wang","year":"2025","journal-title":"BMJ Open."},{"key":"10.1016\/j.critrevonc.2026.105598_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41392-025-02544-w","article-title":"Perioperative penpulimab-based combination therapy in patients with resectable non-small cell lung cancer (ALTER-L043): an open-label, multicenter, randomized, phase II trial","volume":"11","author":"Wang","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105598_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105598_bib49","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0347","article-title":"TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial","author":"Xu","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105598_bib50","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1007\/s12094-024-03442-3","article-title":"Comparison of efficacy and safety of PD-1\/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis","volume":"26","author":"Yang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105598_bib51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cpt.2024.02.001","article-title":"Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: a multicenter, open-label, single-arm phase II trial","volume":"2","author":"Zhang","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.critrevonc.2026.105598_bib52","article-title":"Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: a case report","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105598_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.65364\/iomj.2026.07","article-title":"Expert consensus on immune checkpoint inhibitors for non-small cell lung cancer","volume":"1","author":"Zheng","year":"2026","journal-title":"Int. Open. Med. J."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105598_bib54","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s00262-022-03160-1","article-title":"Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers","volume":"71","author":"Zheng","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105598_bib55","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.35259","article-title":"Phase 1b\/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204)","volume":"130","author":"Zheng","year":"2024","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105598_bib56","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105598_bib57","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1097\/JS9.0000000000002714","article-title":"Efficiency and safety of neoadjuvant PD-1 inhibitor (penpulimab) combined with chemotherapy in resectable N1\/N2 nonsmall cell lung cancer: a prospective cohort study","volume":"111","author":"Zhou","year":"2025","journal-title":"Int. J. Surg."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:07:50Z","timestamp":1793088470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":57,"alternative-id":["S1040842826004853"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105598","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105598"}}